Olema Pharmaceuticals (OLMA) EBITDA (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of EBITDA data on file, last reported at -$54.2 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$54.2 million, down 79.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$186.0 million (down 44.81% YoY), and the FY2025 annual result was -$162.0 million, down 24.9% from the prior year.
• EBITDA eased to -$54.2 million in Q1 2026 per OLMA's latest filing, from -$46.0 million in the prior quarter.
• Over five years, EBITDA peaked at -$19.6 million in Q2 2023 and troughed at -$54.2 million in Q1 2026.
• A 5-year average of -$32.2 million and a median of -$30.5 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA tumbled 104.97% in 2022, then soared 41.61% in 2023.
• A 5-year view of EBITDA shows it stood at -$25.3 million in 2022, then dropped by 3.42% to -$26.2 million in 2023, then decreased by 29.42% to -$33.9 million in 2024, then tumbled by 35.64% to -$46.0 million in 2025, then decreased by 17.85% to -$54.2 million in 2026.
• Business Quant data shows OLMA's EBITDA at -$54.2 million in Q1 2026, -$46.0 million in Q4 2025, and -$42.0 million in Q3 2025.